Purpose. Resistant Gram-negative bacterial (GNB) infections, apart from tremendously escalating the cost of treatment, are a cause for substantial morbidity and mortality among hospitalized patients. Such bacteria are rapidly acquiring resistance to many antimicrobial agents, especially the beta-lactams which are the most frequently prescribed antimicrobials in hospital and community patient care settings, and now also to colistin; a last-line drug to treat infections with such bacteria. The greatest threat to antimicrobial treatment is the production of metallo beta-lactamases, and plasmid-mediated serine carbapenemases.
INTRODUCTION
One of the greatest healthcare challenges mankind has faced is antimicrobial resistance, especially among Gram-negative bacteria (GNB), which is alarmingly increasing worldwide. Such bacteria are rapidly acquiring resistance to many antimicrobial agents, especially the beta-lactams which are the most commonly prescribed antimicrobials in hospitals and community patient care settings. Highlighting the graveness and urgency of this global issue is the discovery of the plasmid-borne mcr-1 gene that confers resistance to colistin [1] ; a last-line drug to treat infections with such bacteria. Resistant GNB infections, apart from tremendously increasing the cost of treatment, are a cause for substantial morbidity and mortality among hospitalized patients.
The greatest threat to antimicrobial treatment is the production of metallo beta-lactamases, and plasmid-mediated serine carbapenemases. The standard phenotypic screening methods widely used may not project the true picture of the prevalence of these beta-lactamases conferring resistance to the bacteria. This not only hinders the antibiotic treatment but also leads to misuse, and abuse of antibiotics, the latter being of utmost concern at this stage.
Since a bacterial strain may carry multiple resistance genes, it is essential to use polymerase chain reaction (PCR)-based methods to characterize all the genes in order to ascertain the prevalence of these beta-lactamases. Thus, we conducted a study over a period of two years, using PCR to ascertain the actual prevalence of these beta-lactamases among the nosocomial multi-resistant GNB isolated from intensive care units (ICUs) of hospitals of northern and southern India. Knowledge of this epidemiology and geographic prediction for these beta-lactamases would help in predicting the empiric antimicrobial treatment and formulation of antibiotic policies.
METHODS
The study was conducted on Gram-negative isolates recovered from clinical samples of patients admitted to the following hospitals (in order of ascending bed strength):
North India: 
Strain selection
Consecutive, non-duplicate GNB isolates recovered from clinical samples of patients, which fulfilled the screening criteria mentioned below were included in the study. The strains were collected consecutively for two months each from 2013 to 2015 to obtain temporally representative data.
Screening of GNB isolates for inclusion in the study A total of 761 non-duplicate nosocomial GNB were included in the study from North (554; 73 %) and South (207; 27 %) Indian hospitals. All these strains were subjected to Clinical and Laboratory Standards Institute (CLSI) recommended screening tests for detection of beta-lactamases [extended spectrum beta-lactamases (ESBLs), AmpC and carbapenemases] production [3] . Phenotypic screening for ESBL production was done against ceftazidime, cefotaxime, ceftriaxone, cefpodoxime and aztreonam; for AmpC production, against cefoxitin; and for carbapenamases, against imipenem and meropenem, by disc diffusion testing on Mueller Hinton Agar (MHA) using CLSI recommended conditions [4] . These 761 strains were positive for at least two of the three beta-lactamases studied. All these strains were also positive for the phenotypic confirmatory tests recommended by CLSI; for ESBLs, cefotaxime and cefotaxime/ clavulanic acid, ceftazidime and ceftazidime/clavulanic acid; for AmpC, AmpC disc test; and for carbapenemases, modified Hodge test (MHT). These strains were further subjected to genotypic testing using PCR for detection of clinically important beta-lactamase genes mediating resistant phenotypes among these isolates.
Preparation of template DNA for PCR Genomic DNA was extracted with QIAamp DNA mini kit (Qiagen, Hilden, Germany).
PCR-based identification of beta-lactamases genes
The reactions were carried out using GenePro Thermal Cycler (Hangzhou Bioer Technology, Bioer, China) in 25 µl volume, containing 20 pmoles of primers (0.6 µM of each Tables 1, 2 and 3 [5] [6] [7] [8] [9] . The PCR programme consisted of an initial denaturation step at 94 C for 3 min, primer annealing at the annealing temperatures (specified for each gene) for 30s, followed by 35 cycles of DNA amplification at 94 C for 30s, and elongation at 72 C for 1 min. After the last cycle, a final extension step at 72 C for 7 min was added. 5 µl aliquots of PCR product was then analysed by gel electrophoresis with 1.5 % agarose. Gels were stained with ethidium bromide at 10 µg ml À1 and visualized using a gel-documentation system. A 100 bp DNA ladder was used as a marker. PCR mixtures with the addition of water instead of template DNA served as the negative control. Klebsiella pneumoniae subsp. pneumoniae (ATCC 700603) (ESBL producer, SHV positive), Klebsiella pneumoniae (ATCC BAA-1144) (Low level AmpC producer) and Enterobacter cloacae subsp. cloacae (ATCC BAA-1143) (high level AmpC producer), Klebsiella pneumoniae (ATCC BAA-1705) (KPC positive), Enterobacter cloacae (ATCC BAA-2468) (NDM1 positive) and clinical GNB strains isolated in the laboratory, served as positive controls for PCR-based detection of beta-lactamase genes.
RESULTS
Among the total 761 GNB, Escherichia coli, Acinetobacter spp., Klebsiella spp., Pseudomonas spp., Enterobacter spp. and others were 27, 23, 21, 17, 5 and 7 % respectively, as shown in Table 4 . The most predominant GNB in the north were Acinetobacter spp. (154, 28 %), followed by Pseudomonas spp. (114, 21 %); closely followed by Escherichia coli (110, 20 %) and Klebsiella pneumoniae (101, 18 %); while down south, the most prevalent organism was Escherichia coli (94, 45 %) followed by Klebsiella pneumoniae (59, 29 %) and Acinetobacter baumannii (21, 10 %). Most of the bacterial strains were recovered from tracheal aspirate samples (115, 20.8 %) followed by wound samples (99, 17.9 %) in the north, while the maximum bacterial strains were isolated from urine samples (96, 46.4 %) in South India (Table 5 ).
Genotypic profile of beta-lactamases
The prevalence of beta-lactamase genes in various Gramnegative organisms isolated from North and South India are provided in Tables 6 and 7 respectively. All three categories of beta-lactamase genes were found to be present in Acinetobacter spp., Escherichia spp., Enterobacter spp., Klebsiella spp.and Pseudomonas spp. A. ESBLs A high prevalence of ESBL genes was found across all genera in these strains. It was higher in North Indian strains than in those from the south. The most prevalent ESBL gene was observed to be bla TEM (25-73 % positivity) across all genera studied, followed by bla CTX-M-1 (25-100 % positivity), in both North and South Indian strains. The prevalence of bla VEB was found to be the least.
B. AmpC
The level of AmpC production was comparatively lower in both North and South Indian strains. AmpC genes were the least prevalent of all the three beta-lactamases studied.
bla FOX-1 to bla FOX-5B being the most common AmpC gene among all the isolates.
C. Carbapenemases
The carbapenem resistance was higher in North than in South Indian GNB. bla OXA-1 was the most common carbapenemase gene among the South Indian strains, while bla NDM-1 , followed by bla OXA-1 were the two most prevalent carbapenemase genes in the North Indian isolates.
DISCUSSION
The increase in antibiotic resistance among GNB is a notable example of how bacteria can procure, maintain The total number of each strain of bacteria from North and South India are written in bold. and express new genetic information that can confer resistance to one or several antibiotics. This problem facing the world is of particular concern in the ICU setting. Resistant GNB infections, apart from tremendously increasing the cost of treatment, are a cause for substantial morbidity and mortality among hospitalized patients. Major technical issues, such as false positive/negative results due to masking effects of multiple beta-lactamase genes, low detection limits and constantly evolving pathogens, seriously thwart attempts for successful antimicrobial treatment and disease control.
With the global increase in the occurrence, types and rate of dissemination of ESBLs, AmpC and carbapenemases, early detection is critical. beta-lactamases show tremendous variation in geographic distribution. Thus, their detection and characterization is important from an epidemiological, clinical, laboratory and infection control point of view. The prompt detection of various betalactamases is important for optimizing treatment and for epidemiological tracing of resistance determinants. The benefits of early detection also include timely implementation of strict infection control practices as well as clinical guidance regarding the potential risks for therapeutic failure. Accurate prevalence data are also required to evaluate the success of control measures.
A high rate of antimicrobial resistance is seen in Gramnegative pathogens at AIIMS and its Trauma Centre. Carbapenem resistance in Pseudomonas spp., Acinetobacter spp. and Klebsiella spp. was 7, 74 and 24 % in 2011 at the Trauma Centre [10] . In a study published in 2014, 76 % of Pseudomonas spp. at our centre was carbapenem resistant [11] . There are no published data on antimicrobial resistance (AMR) from both the South Indian hospitals included in this study. However, the prevalence of AMR in South India is generally lower than in North India [12] .
Our study encompasses a large number of clinical isolates from North and South India. We found a high prevalence of beta-lactamase genes across all genera of GNB. Many of these were positive for two or more different types of beta-lactamases. ESBLs were the most prevalent beta-lactamases followed by carbapenemases and AmpC. Such phenomenon poses problems in phenotypic testing for betalactamases and may result in inadvertent errors in antimicrobial treatment. CLSI guidelines recommend phenotypic confirmation for only a limited genera and species. With the increasing prevalence of other genera like Acinetobacter, Stenotrophomonas, Burkholderia, Serratia and many others, causing hospital-acquired infections, we have to resort to molecular methods for confirmation of betalactamase production.
Our findings would help to obtain a clear picture of the pattern of antimicrobial resistance in the North and South Indian hospitals included in this study. These data would Stenotrophomonas spp.
n=3 ( 57 (56) 30 (26) 8 (47) 1 (9) 1 (100) 2 ( 43 (43) 19 (17) 1 (6) 1 ( ultimately help in framing antimicrobial prescription policies for India.
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